"Zidovudine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.
| Descriptor ID |
D015215
|
| MeSH Number(s) |
D03.383.742.680.705.950 D13.570.230.500.950 D13.570.230.855.950 D13.570.685.705.950
|
| Concept/Terms |
Zidovudine- Zidovudine
- Azidothymidine
- AZT Antiviral
- 3'-Azido-3'-deoxythymidine
- 3' Azido 3' deoxythymidine
- AZT (Antiviral)
- 3'-Azido-2',3'-Dideoxythymidine
- 3' Azido 2',3' Dideoxythymidine
- AZT, Antiviral
- Antiviral AZT
|
Below are MeSH descriptors whose meaning is more general than "Zidovudine".
Below are MeSH descriptors whose meaning is more specific than "Zidovudine".
This graph shows the total number of publications written about "Zidovudine" by people in this website by year, and whether "Zidovudine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 2 | 2 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 2 | 1 | 3 |
| 2010 | 2 | 2 | 4 |
| 2011 | 2 | 1 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 3 | 1 | 4 |
| 2014 | 0 | 2 | 2 |
| 2015 | 0 | 3 | 3 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 1 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 2 | 2 |
| 2020 | 1 | 0 | 1 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Zidovudine" by people in Profiles.
-
Abacavir safety and effectiveness in young infants with HIV in South African observational cohorts. Antivir Ther. 2023 02; 28(2):13596535231168480.
-
Maternal and infant renal safety following tenofovir disoproxil fumarate exposure during pregnancy in a randomized control trial. BMC Infect Dis. 2022 Jul 20; 22(1):634.
-
Minimal Cross-resistance to Tenofovir in Children and Adolescents Failing ART Makes Them Eligible for Tenofovir-Lamivudine-Dolutegravir Treatment. Pediatr Infect Dis J. 2022 10 01; 41(10):827-834.
-
The association between HIV tri-therapy with the development of Type-2 Diabetes Mellitus in a rural South African District: A case-control study. PLoS One. 2020; 15(12):e0244067.
-
Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination: a comparative analysis. AIDS. 2019 12 01; 33(15):2403-2413.
-
Descriptive analysis of World Health Organization-recommended second-line antiretroviral treatment: A retrospective cohort data analysis. S Afr Med J. 2019 Nov 27; 109(12):919-926.
-
Poor Obstetric and Infant Outcomes in Human Immunodeficiency Virus-Infected Pregnant Women With Tuberculosis in South Africa: The Tshepiso Study. Clin Infect Dis. 2018 03 05; 66(6):921-929.
-
Submicron Matrices Embedded in a Polymeric Caplet for Extended Intravaginal Delivery of Zidovudine. AAPS J. 2017 11; 19(6):1745-1759.
-
Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. PLoS One. 2017; 12(7):e0181357.
-
Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention. N Engl J Med. 2016 11 03; 375(18):1726-1737.